2cureX: Shift in management

Redeye Research Note 2021/01/05

Redeye views the shift in management, appointing Fernando Andreu as new CEO of 2cureX, as positive. We argue that his extensive commercial experience in the field should be a good fit for the phase 2cureX now is in; early commercialization of IndiTreat in the EU.

Oscar Bergman

Equity Analyst

2cureX: Shift in management

Redeye Research Note timeStamp 2021/01/05

Tagged companies

You need to be a Redeye member to access this content

Become a member to:

Redeye Research Note 2021/01/05